Su2065 Qualitative Assessment of Symptom Experience in Patients With Irritable Bowel Syndrome for the Development of Patient-Reported Outcome Instruments

for the Development of Patient Reported Outcome Instruments Mollie J. Baird, MPH1; Robyn T. Carson, MPH2, Claire Ervin, MPH3; Lin Chang, MD4; Brennan Spiegel, MD4; Nancy J. Norton5; Jeffrey Lackner, PsyD6; Karen Lasch, MD7; and Sheri E. Fehnel, PhD3 on Behalf of the Critical Path Institute PRO Consortium's Irritable Bowel Syndrome Working Group 1Ironwood Pharmaceuticals, Cambridge, MA, USA; 2Forest Research Institute, Jersey City, NJ, USA; 3RTI Health Solutions, Research Triangle Park, NC, USA; 4Division of Digestive Diseases, University of California, Los Angeles, CA, USA; 5International Foundation for Functional Gastrointestinal Disorders, Milwaukee, WI, USA; 6University of Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA; 7Takeda Pharmaceuticals, Chicago, IL, USA